注射用丹酚酸A防治肝纤维化的实验研究

目的探讨注射用丹酚酸A抗肝纤维化的作用,为丹酚酸A的临床应用提供理论依据。方法采用CCl4体外诱导肝细胞损伤,观察丹酚酸A对肝细胞活性及其细胞培养上清液ALT、AST、LDH水平和细胞裂解液中SOD活性和MDA含量的变化;另采用皮下注射CCl4诱导大鼠肝纤维化模型,观察丹酚酸A对肝纤维化大鼠血清LN、HA、SOD和MDA含量的影响以及肝脏组织病理改变情况。结果与模型对照组比,丹酚酸A高、低剂量组和Vit E组的细胞存活率显著提高(P0.01),丹酚酸A高剂量组ALT、AST和LDH活性显著降低(P0.01),丹酚酸A高剂量组和Vit E组SOD活性明显升高(P0.05),MDA含量显著降低(P0.05);体内试验发现,与模型对照组比,丹酚酸A高剂量组纤维化大鼠的血清LN和HA水平显著降低(P0.05),高、低剂量组SOD活性显著升高(P0.05,P0.01),MDA含量显著降低(P0.01,P0.05),并能改善肝脏病理形态。结论注射用丹酚酸A可通过抗脂质过氧化作用,起到保护肝细胞,减轻肝纤维化的作用。

Effects of Salvianolic Acid A Injection on CCl4 Induced Hepatocyte Injury and Hepatic Fibrosis in Rats

Objective To study on the anti-hepatic fibrosis effects of salvianolic acid A injection (SAA), and further to provide the theoretical basis for the clinical application. Methods Using CCl₄ induced hepatocyte injury in vitro, the hepatocyte viability, the levels of ALT, AST and LDH in cell culture supernatants and the levels of SOD and MDA in cell lysates were detected. In addition, the hepatic fibrosis rat model was made by subcutaneous injection of CCl₄, the serum LN, HA, SOD and MDA levels were detected and the pathological changes in liver tissue were also observed. Results Compared with model group, the hepatocyte viability in SAA high or low dose group and Vit E group were significantly increased (P< 0.01), and the activities of ALT, AST and LDH in SAA high dose group were significantly lowed (P< 0.01). The activity of SOD in SAA high dose group and Vit E group was significantly increased (P< 0.05), while MDA content was decreased (P< 0.05). Vivo test showed that the levels of serum LN and HA in SAA high dose group were significant lower than those of hepatic fibrosis rat model group (P< 0.05). Moreover, the activity of SOD in SAA high or low dose group was significantly increased (P< 0.05,P< 0.01), while MDA content was lowed (P< 0.05,P< 0.01), and can improve the pathological of liver tissues. Conclusions SAA injection can anti-lipid peroxidation and thereby protect hepatocyte and reduce hepatic fibrosis.